Genomic profiling of pleomorphic and florid lobular carcinoma in situ reveals highly recurrent ERBB2 and ERRB3 alterations
- PMID: 31932682
- DOI: 10.1038/s41379-020-0459-6
Genomic profiling of pleomorphic and florid lobular carcinoma in situ reveals highly recurrent ERBB2 and ERRB3 alterations
Abstract
Pleomorphic LCIS (P-LCIS) and florid LCIS (F-LCIS) are morphologic variants distinguished from classic LCIS by marked nuclear pleomorphism and/or an expansile growth pattern with or without necrosis. Given the rarity of these LCIS variants, little data exist regarding their molecular pathogenesis, natural history, and optimal management. The purpose of this study was to genomically profile LCIS variants to gain further insight into their biology. Nineteen cases of pure LCIS variants (17 P-LCIS, 2 F-LCIS) diagnosed on core needle biopsy at our institution from 2006 to 2017 were included, five of which were upgraded to invasive cancer at excision. Macrodissected lesions were analyzed by a hybrid-capture next generation sequencing assay that surveyed exonic sequences of 447 genes for mutations and copy number variations (CNVs) and 191 regions across 60 genes for structural rearrangements. LCIS variants were all confirmed as E-cadherin negative by immunohistochemistry. Receptor profiles among the 17 P-LCIS cases included HR+/HER2- (nine cases), HR+/HER2+ (three cases), HR-/HER2+ (two cases), and HR-/HER2- (three cases). The two F-LCIS cases were HR+/HER2- and HR+/HER2+. All LCIS variants had genetic alterations consistent with a lobular phenotype including 1q gain (16 cases), 16q loss (18 cases), and CDH1 mutations (18 cases). Highly recurrent ERBB2 alterations were noted including mutations (13 cases) and amplifications (six cases). Other significant alterations included mutations in PIK3CA (six cases), RUNX1 (four cases), ERBB3 (four cases), and CBFB (three cases), as well as amplification of CCND1 (five cases). A TP53 mutation was identified in one case of HR-/HER2+ P-LCIS with signet ring cell features that lacked 1q gain and 16q loss. P-LCIS and F-LCIS contain genetic alterations characteristic of lobular neoplasia; however, these LCIS variants are distinguished from classical LCIS reported in the literature by their highly recurrent ERBB2 alterations.
Similar articles
-
Genetic analysis of pleomorphic and florid lobular carcinoma in situ variants: frequent ERBB2/ERBB3 alterations and clonal relationship to classic lobular carcinoma in situ and invasive lobular carcinoma.Mod Pathol. 2020 Jun;33(6):1078-1091. doi: 10.1038/s41379-019-0449-8. Epub 2020 Jan 6. Mod Pathol. 2020. PMID: 31907376
-
Invasive lobular carcinoma with extracellular mucin (ILCEM): clinicopathologic and molecular characterization of a rare entity.Mod Pathol. 2022 Oct;35(10):1370-1382. doi: 10.1038/s41379-022-01084-w. Epub 2022 Apr 27. Mod Pathol. 2022. PMID: 35477749
-
PIK3CA mutations are common in lobular carcinoma in situ, but are not a biomarker of progression.Breast Cancer Res. 2017 Jan 17;19(1):7. doi: 10.1186/s13058-016-0789-y. Breast Cancer Res. 2017. PMID: 28095868 Free PMC article.
-
Current Concepts in Diagnosis, Molecular Features, and Management of Lobular Carcinoma In Situ of the Breast With a Discussion of Morphologic Variants.Arch Pathol Lab Med. 2017 Dec;141(12):1668-1678. doi: 10.5858/arpa.2016-0421-RA. Epub 2017 Jun 2. Arch Pathol Lab Med. 2017. PMID: 28574280 Review.
-
Non-invasive lobular neoplasia of the breast: Morphologic features, clinical presentation, and management dilemmas.Breast J. 2020 Jun;26(6):1148-1155. doi: 10.1111/tbj.13857. Epub 2020 Jun 4. Breast J. 2020. PMID: 32500575 Review.
Cited by
-
Morphologic subtypes of lobular carcinoma in situ diagnosed on core needle biopsy: clinicopathologic features and findings at follow-up excision.Mod Pathol. 2021 Aug;34(8):1495-1506. doi: 10.1038/s41379-021-00796-9. Epub 2021 Apr 6. Mod Pathol. 2021. PMID: 33824462 Free PMC article.
-
Update on lobular lesions of the breast.Histopathology. 2023 Jan;82(1):36-52. doi: 10.1111/his.14829. Histopathology. 2023. PMID: 36482279 Free PMC article. Review.
-
Presence of Non-classic LCIS Is Not a Contraindication to Breast Conservation in Patients with Concomitant Invasive Breast Cancer or DCIS.Ann Surg Oncol. 2022 Nov;29(12):7696-7702. doi: 10.1245/s10434-022-12066-2. Epub 2022 Jun 30. Ann Surg Oncol. 2022. PMID: 35771367
-
The Genomic Landscape of Lobular Breast Cancer.Cancers (Basel). 2021 Apr 18;13(8):1950. doi: 10.3390/cancers13081950. Cancers (Basel). 2021. PMID: 33919581 Free PMC article.
-
An update on intraductal and intralobular proliferative lesions of the breast.Rev Assoc Med Bras (1992). 2023 Aug 4;69(suppl 1):e2023S121. doi: 10.1590/1806-9282.2023S121. eCollection 2023. Rev Assoc Med Bras (1992). 2023. PMID: 37556640 Free PMC article. No abstract available.
References
-
- Haagensen CD, Lane N, Lattes R, Bodian C. Lobular neoplasia (so-called lobular carcinoma in situ) of the breast. Cancer. 1978;42:737–69. - PubMed
-
- Dabbs DJ, Schnitt SJ, Geyer FC, Weigelt B, Baehner FL, Decker T, et al. Lobular neoplasia of the breast revisited with emphasis on the role of E-cadherin immunohistochemistry. Am J Surg Pathol. 2013;37:e1–11. - PubMed
-
- Canas-Marques R, Schnitt SJ. E-cadherin immunohistochemistry in breast pathology: uses and pitfalls. Histopathology. 2016;68:57–69. - PubMed
-
- National Comprehensive Cancer Network (US) Clinical practice guidelines in oncology, breast cancer (version 3.2019). Fort Washington, PA: National Comprehensive Cancer Network (US); 2019. https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf . Accessed on 11/02/2019.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous